 BASEL, Switzerland, April 05, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV, a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with expertise in building and leading commercial teams accompanied by a record of successful product launches. She most recently served as Vice President, Neurological Rare Diseases at Genentech. Ms. Merendino will be a member of Myovants Executive Committee, reporting directly to Chief Executive Officer David Marek. 